Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice
Elia Tamagnini, Luca Simonelli, Martin Palus, Tanja Rezzonico Jost, Edoardo Lazzarini, Davide Mangani, Václav Hönig, Markéta Dvořáková, Dominik Arbon, Federica Gambini, Sara Lestani, Fabio Grassi, Lucio Barile, Mattia Pedotti, Radislav Sedlacek, Luca Varani · 2026
Read Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice by Elia Tamagnini, Luca Simonelli, Martin Palus, Tanja Rezzonico Jost, Edoardo Lazzarini, Davide Mangani, Václav Hönig, Markéta Dvořáková, Dominik Arbon, Federica Gambini, Sara Lestani, Fabio Grassi, Lucio Barile, Mattia Pedotti, Radislav Sedlacek, Luca Varani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13418380.txt.
Introduction
Elia Tamagnini and colleagues engineer a coronavirus spike protein that can no longer grip its human receptor yet still trains immunity, in a 2026 mouse study. Vaccines use spike to raise antibodies, but spike's grip on the ACE2 receptor has been proposed as a factor in rare side effects. Point changes were designed to break that grip while keeping the protein's shape.
Mutant spikes bound ACE2 poorly in lab tests. In mice they raised immune responses equal to or better than the natural spike and protected animals on challenge. The design offers a template for vaccine antigens stripped of unwanted host interactions.
Catalog record
| CREATOR | Elia Tamagnini, Luca Simonelli, Martin Palus, Tanja Rezzonico Jost, Edoardo Lazzarini, Davide Mangani, Václav Hönig, Markéta Dvořáková, Dominik Arbon, Federica Gambini, Sara Lestani, Fabio Grassi, Lucio Barile, Mattia Pedotti, Radislav Sedlacek, Luca Varani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22741 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice Authors: Elia Tamagnini, Luca Simonelli, Martin Palus, Tanja Rezzonico Jost, Edoardo Lazzarini, Davide Mangani, Václav Hönig, Markéta Dvořáková, Dominik Arbon, Federica Gambini, Sara Lestani, Fabio Grassi, Lucio Barile, Mattia Pedotti, Radislav Sedlacek, Luca Varani Published: 2026 ABSTRACT Background: While vaccines are designed to elicit targeted immune responses, in some cases, the immunogenic molecules employed can inherently interact with broader host cellular pathways as a secondary consequence. This phenomenon can be exemplified by COVID-19 vaccines. COVID-19 vaccines, including mRNA platforms, use the SARS-CoV-2 spike protein as an immunogen to induce the production of neutralizing antibodies. The spike protein binds the ACE2 (angiotensin-converting enzyme 2) receptor on human cells, mediating viral entry and infection. ACE2 is widely expressed across multiple tissues and is a key component of the renin–angiotensin–aldosterone system (RAAS) that acts as a homeostatic regulator of systemic and local blood flow, blood pressure, cardiac function, fluid balance and immunity. Some studies have proposed the interaction between the spike protein and ACE2 as a possible contributing factor to rare adverse effects observed following COVID-19 vaccination, including myocarditis, pericarditis, thrombosis, and reported alterations in blood pressure, though these mechanisms remain to be fully elucidated. Objectives: As a proof-of-concept approach in vaccine antigen development, we engineered SARS-CoV-2 spike mutants with impaired binding to the host receptor ACE2. Methods: By rational design, we produced and validated in vitro and in vivo spike point mutants that do not effectively bind ACE2. Results: The engineered spike mutants do not effectively bind the human entry receptor ACE2 while retaining the immunogenic properties equal to or better than the wild type spike and thus generate a protective response in animals when used as a vaccination agent. Conclusions: By establishing a straightforward molecular strategy for rational vaccine design, this work demonstrates the feasibility of limiting specific antigen–host receptor interactions while maintaining immunogenicity. This approach may be applicable to future vaccination strategies where antigen interaction with host cells could potentially interfere with physiological pathways. 1. Introduction During the COVID-19 pandemic, a global vaccination campaign resulted in the administration of over thirteen billion doses [1,2]. While vaccines have proven safe and effective, like any therapeutic intervention, they can cause adverse effects (AEs). Whereas most reported AEs are mild and temporary, including fever, fatigue, headache, chills, myalgia, arthralgia and lymphadenopathy [3,4], some more severe but less frequent AEs have been described. These include anaphylaxis [5,6,7], autoimmune reactions [8], cardiovascular events (e.g., myocarditis, pericarditis) [9,10,11], thrombosis [12,13], blood pressure alterations [14,15], and menstrual disturbances in young girls after COVID-19 vaccination [16]. Cardiovascular events were particularly notable in younger individuals [17], leading some countries to discourage specific vaccines for males under 30 [18]. Although the exact number of cases varies vastly across scientific literature, there is consensus on the incidence of myocarditis in young males, up to 40 cases per 100,000 individuals under 40, with the highest risk among the 12–24 age group [14]. The total incidence of total venous thrombosis after vaccination is estimated at 28 per 100,000, with a predominance of women (70%) of whom about half are under the age of 50 [19,20,21]. The molecular mechanisms underlying these cardiovascular AEs remain to be determined. One hypothesis that has been proposed implicates interaction between the SARS-CoV-2 spike protein and its human entry receptor, angiotensin-converting enzyme (ACE2) [22,23]. ACE2 is widely expressed in human tissues, particularly in the cardiovascular system where it regulates the renin–angiotensin–aldosterone system (RAAS) [24,25,26]. RAAS plays a crucial role in cardiovascular homeostasis, and it has been hypothesized that this system could potentially provide a link between vaccination and some observed AEs. Some research has suggested that spike protein binding to ACE2 might disrupt RAAS balance, though the clinical relevance of these findings remains to be established [24,27]. We hypothesized that preserving the ability of the spike vaccination agent to generate a protective immune response while impairing its interaction with ACE2 could provide a valuable research tool for investigating the potential role of spike-ACE2 interactions in vaccination outcomes. We set forth to generate spike protein mutants with compromised ACE2 binding affinity. We show that these mutants retain the ability to generate a protective response, which was equal to or better than the wild-type spike. Altogether, our findings demonstrate the technical feasibility of impairing specific antigen–receptor interactions while maintaining immunogenicity. This rational design approach may inform future vaccine development strategies where antigen interactions with host receptors could potentially interfere with physiologically relevant pathways beyond COVID-19. 2. Materials and Methods 2.1. Spike-ACE2 Structural Analysis PyMOL [28] was employed to visualize the 3D structure of the spike-ACE2 complex (PDB code: 7XO5) [29], defining the SARS-CoV-2 RBD interaction interface as any residue located within 7 Å of ACE2. In this study, the visual structural analysis was utilized to map critical chemical interactions and characterize the essential residues driving the RBD-ACE2 binding affinity. 2.2. Protein Expression and Purification Recombinant RBD mutants: to express SARS-CoV-2 RBD, a codon-optimized gene encoding residues 316–534 (GenBank (https://www.ncbi.nlm.nih.gov/genbank/): UFO69279.1 (accessed on 1 June 2023)) with a C-terminal 8× HisTag was synthesized and cloned into the mammalian expression vector pcDNA3.1(+) by Genscript. RBD mutations were introduced in the gene by single-point mutations (Genscript, Piscataway, NJ, USA). The resulting variants were produced by transient PEI transfection in Expi293F cells (ThermoFisher, Waltham, MA, USA). Six days post-transfection, the proteins were purified from the cell supernatants using affinity chromatography (HiTrap Chelating HP, Cytiva, Marlborough, MA, USA), followed by size-exclusion chromatography (SEC 75, Cytiva). Recombinant ACE2: ACE2 fused to the Fc region of mouse IgG at the C terminus was synthesized and cloned into the mammalian expression vector pcDNA3.1(+). ACE2 was produced by transient PEI transfection in Expi293F cells (Thermo Fisher), purified from the cell supernatants 6 days after transfection by affinity chromatography (HiTrap Chelating HP, Cytiva) followed by size exclusion chromatography (SEC 75, Cytiva). All proteins were analyzed by SDS–PAGE and underwent quality control and biophysical characterization to ensure functionality, stability, lack of aggregation and batch-to-batch reproducibility. 2.3. Analysis of RBD-ACE2 Binding Interactions ELISA: 96-well ELISA plates were coated at 4 °C overnight with 180 nM RBD, and then washed and blocked with PBS containing 10% FBS. ACE2 was then added in a 1:3 serial dilution, starting from 250 nM for wtRBD and R493A and 1000 nM for the remaining mutants. After a 1 h incubation at room temperature and subsequent washing, the binding between the RBD mutants and ACE2 was detected using goat anti-mouse IgG conjugated to alkaline phosphatase (1:500 dilution; Southern Biotech, Birmingham, AL, USA). The experiment was performed in duplicate, and the mean of the two replicates was reported; error bars represent the standard deviation of the measured values. Absorbance was measured using a microplate reader with Gen5 software version 1.11.5 (BioTek Instruments, Winooski, VT, USA). Surface Plasmon Resonance (SPR): RBD mutants′ binding kinetics were characterized at 25 °C using a Biacore 8K instrument (GE Healthcare, Chicago, IL, USA). The running buffer consisted of 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) Tween-20. RBD protein was covalently immobilized at 150 nM onto CM5 sensor chips (Cytiva, Marlborough, MA, USA) via standard amine coupling chemistry. Single-cycle kinetics were performed by sequentially injecting five